UTHR
UNITED THERAPEUTICS Corp
Next earnings Jul 28, 2026 (before open) · consensus $7.25 EPS, $825M rev
Last earnings +4.3% on 2026-05-06
$542.66
▼ -0.13%$542.66▲ +89.48%
over 1Y
L $274.70EODHDH $596.76
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.1%
1W+0.8%
1M-4.9%
3M+3.8%
YTD+9.2%
1Y+89.5%
Buy
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 22 analysts
Buy
Elite-margin PAH compounder with a fortress balance sheet trading at a reasonable ~19x EPS — quality at a fair price.
Revenue $3.18B · FY2025
The read
Quality fundamentals and an attractive price line up (~50% below fair value) — the rarer case where both the business and the entry look good.
United Therapeutics is a rare combination of durable, profitable growth and an exceptionally clean balance sheet. Revenue has nearly doubled from $1.69B (FY2021) to $3.18B (FY2025), with net income up from $476M to $1.33B over the same span — FY2025 alone grew revenue +10.6% and net income +11.7%, with diluted EPS up +13.1% to $27.86, helped by a -2.4% reduction in shares from $1.0B of buybacks. Profitability is outstanding: 87.9% gross margin, 46.9% operating margin, and 41.9% net margin, with operating cash flow of $1.56B (+17.6%). The balance sheet is fortress-grade — liabilities/equity of just 0.11x, $7.10B of stockholders' equity, $1.56B cash, and current assets ($3.70B) dwarfing current liabilities ($561M). ROE of 18.8% is solid given the company carries almost no leverage.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.69B | $1.94B | $2.33B | $2.88B | $3.18B |
| Gross profit | $1.56B | $1.78B | $2.07B | $2.57B | $2.80B |
| Operating income | $556M | $980M | $1.18B | $1.38B | $1.49B |
| Net income | $476M | $727M | $985M | $1.20B | $1.33B |
| Diluted EPS | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |
| Net margin | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$22.2B
EV / EBITDA14.1
EV / Sales7.0
EV / FCF21.4
P / FCF22.9
PEG (trailing)1.67
Earnings yield5.6%
FCF yield4.4%
Quality & risk
ROIC (est.)16.6%
Free cash flow$1.04B
Total debt—
Net cash$1.56B
Altman Z-Score21.23 safe
Piotroski F-Score7/8
Capital returns
Buyback yield4.2%
Dividend yield (est.)—
Shareholder yield4.2%
Shares Δ YoY-2.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-252026-06-26open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-232026-06-24open ↗4Period ending 2026-06-222026-06-24open ↗4Period ending 2026-06-222026-06-23open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-18open ↗4Period ending 2026-06-172026-06-18open ↗144Filing2026-06-18open ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-152026-06-16open ↗
Frequently asked
- Is UNITED THERAPEUTICS Corp (UTHR) a buy?
- UTHR currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Elite-margin PAH compounder with a fortress balance sheet trading at a reasonable ~19x EPS — quality at a fair price.
- What is UTHR's fair value?
- A Modified-Graham model based on UTHR's SEC fundamentals estimates a fair value of about $811.49. It is an estimate from reported earnings, not a price target.
- Is UTHR overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, UTHR currently appears undervalued relative to its SEC-grounded earnings power.
- What is UNITED THERAPEUTICS Corp's quality score?
- UTHR scores 79.27450980392155/100 (grade B+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001082554, latest 10-Q filed 2026-05-06) · EODHD · analysis by claude-code · as of 6/21/2026, 7:09:38 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.